Oxford BioMedica (LSE: OXB), the leading gene therapy company, and Cancer Research UK are scheduled to deliver two poster presentations, describing results from Phase II trials of TroVax in colorectal cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held on 2-6 June in Atlanta, Georgia, USA. The Company’s US clinical collaborators have had a further two abstracts, covering preliminary results from clinical trials of TroVax in renal cell carcinoma, selected for publication in the ASCO Proceedings.
